IMAC Holdings, Inc. Announces Completion of Third Cohort of its Phase 1 Clinical Study of Umbilical Cord-Derived Mesenchymal Stem Cells for the…

IMAC Holdings, Inc.

BRENTWOOD, Tenn., Sept. 09, 2022 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) (IMAC or the Company), today announces it has completed the third cohort of its Phase 1 clinical trial for its investigational compound utilizing umbilical cord-derived allogenic mesenchymal stem cells for the treatment of bradykinesia due to Parkinsons disease.

The third cohort consists of five patients with bradykinesia due to Parkinsons disease receiving an intravenous infusion of a high concentration stem cell treatment. The third and final cohort of the Phase 1 clinical trial was completed on Tuesday, September 6, 2022.

About IMACs Phase 1 Clinical Trial

The Phase 1 clinical trial, consisting of a 15-patient dose escalation safety and tolerability study, is being conducted at three of IMACs clinical centers in Chesterfield, Missouri, Paducah, Kentucky, and Brentwood, Tennessee. The trial is divided into three groups: 1) five patients with bradykinesia due to Parkinsons disease received a low concentration dose, intravenous infusion of stem cells, 2) five received a medium concentration intravenous dose, 3) and five received a high concentration intravenous dose. All groups will be subsequently tracked for 12 months. IMACs medical doctors and physical therapists at the clinical sites have been trained to administer the treatment and manage the therapy. Ricardo Knight, M.D., M.B.A., who is medical director of the IMAC Regeneration Center of Chicago, is the trials principal investigator.

The Institute of Regenerative and Cellular Medicine serves as the trials independent investigational review board, while Regenerative Outcomes provides management of the study. Further details of the trial can be found at clinicaltrials.gov.

About Bradykinesia Due to Parkinsons Disease

In addition to unusually slow movements and reflexes, bradykinesia may lead to limited ability to lift arms and legs, reduced facial expressions, rigid muscle tone, a shuffling walk, and difficulty with repetitive motion tasks, self-care, and daily activities. Parkinsons disease is the typical culprit of bradykinesia, and as it progresses through its stages, a persons ability to move and respond declines.

Story continues

According to Zion Market Research, the global Parkinsons disease therapeutics market was $2.61 billion in 2018 and is expected to grow to $5.28 billion by 2025. The Parkinsons Disease Foundation estimates that nearly 10 million people are suffering from Parkinsons disease, and almost 60,000 new cases are reported annually in the U.S.

About IMAC Holdings, Inc.

IMAC Holdingsowns and manages health and wellness centers that deliver sports medicine, orthopedic care, and restorative joint and tissue therapies for movement restricting pain and neurodegenerative diseases.IMACis comprised of three business segments: outpatient medical centers, The Back Space, and a clinical research division. With treatments to address both young and aging populations,IMAC Holdingsowns or manages outpatient medical clinics that deliver regenerative rehabilitation services as a minimally invasive approach to acute and chronic musculoskeletal and neurological health problems. IMACs The Back Company retail spinal health and wellness treatment centers deliver chiropractic care within Walmart locations. IMACs research division is currently conducting a Phase I clinical trial evaluating a mesenchymal stem cell therapy candidate for bradykinesia due to Parkinsons disease. For more information visitwww.imacholdings.com.

# # #

Safe Harbor Statement

This press release contains forward-looking statements. These forward-looking statements, and terms such as anticipate, expect, believe, may, will, should or other comparable terms, are based largely on IMAC's expectations and are subject to a number of risks and uncertainties, certain of which are beyond IMAC's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, risks and uncertainties associated with its ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the skills and experience necessary to meet customers requirements, and its ability to protect its intellectual property. IMAC encourages you to review other factors that may affect its future results in its registration statement and in its other filings with the Securities and Exchange Commission. In light of these risks and uncertainties, there can be no assurance that the forward-looking information contained in this press release will in fact occur.

IMAC Press Contact:

Laura Fristoe

lfristoe@imacrc.com

See the rest here:
IMAC Holdings, Inc. Announces Completion of Third Cohort of its Phase 1 Clinical Study of Umbilical Cord-Derived Mesenchymal Stem Cells for the...

Top 3 grants in regenerative medicine: July 2022 – RegMedNet

This months top grants in regenerative medicine, sourced from Dimensions, includes projects on: a novel platform to enhance single cell interrogation of nervous system development, human endothelial cell regulation of ossification and the development of a dynamic double network hydrogel for generating pancreatic organoids from induced pluripotent stem cells.

This project aims to investigate a strategy, which utilizes novel spatial transcriptomics approaches, integrated multiplexed RNA/protein detection and visualization and computational algorithms to identify and map molecular markers of the preganglionic neurons in the ventral spinal cord and progenitor cell populations of the sympathetic ganglia. If successful, the approach could provide a foundation for basic research of peripheral nervous system birth defects and repair using stem cell-based therapies, as well as future studies of neuroblastoma initiation.

Funding amount:US$206,000

Funding period: 8 August 2022 31 July 2024

Funder:Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Research organization:Stowers Institute for Medical Research (MO, USA)

Read more

Over one million patients undergo bone repair procedures in the USA annually, with autologous bone grafting remaining the preferred treatment for bone defects. The development of therapies that exploit the osteogenic potential of bone marrow-derived mesenchymal stem cells (bm-MSCs) has been limited due to limited understanding of the regulatory mechanisms of in vivo bm-MSC osteogenesis. Previous research from the group showed that the osteogenic potential of bm-MSCs is dependent on sustained proximity to endothelial cells. The goal of the present study is to elucidate the cellular and molecular mechanisms by which endothelial cells regulate the osteogenic differentiation of bm-MSCs and develop a foundation of knowledge upon which to build therapeutic strategies for bone regeneration utilizing autologous bm-MSCs.

Funding amount:US$442,000

Funding period: 10 August 2022 31 May 2027

Funder:National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Research organization:Boston Childrens Hospital (MA, USA)

Read more

Human induced pluripotent stem cells provide a valuable source of cells for basic research and translational applications. While there have been advances in lineage-specific differentiation of human induced pluripotent stem cells, there remains limited understanding on the impact of matrix stiffness, viscoelasticity and integrin ligand presentation on the multi-stage development of exocrine pancreatic organoids. This research aims to define the influence of matrix properties on the generation of exocrine pancreatic organoids by developing a viscoelastic dynamic double network hydrogel platform with controllable matrix mechanical properties and biochemical motifs. This will advance the application of chemically defined matrices as xeno-free artificial stem cell niches for organoid growth and tissue regeneration applications.

Funding amount:US$468,000

Funding period: 1 August 2022 31 July 2026

Funder:National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Research organization: Indiana University Purdue University Indianapolis (IA, USA)

Read more

Brought to you with support from:

View post:
Top 3 grants in regenerative medicine: July 2022 - RegMedNet

Stem Cell Therapy Approach On War Injury Patients – NewsPatrolling

Peshmerga Army Invites Dr Pradeep Mahajan To Addressed a treatment using Stem Cell Therapy on injured wounds

Mumbai: Stem cell therapy possesses both diagnostic and therapeutic potential. The use of stem cells for pain management can help with fast, safe, effective, and lasting results in terms of injuries. Dr. Pradeep Mahajan, Regenerative Medicine Researcher, StemRx Bioscience Solutions Pvt. Ltd conducted a session on the benefits of stem cell therapy to help the Peshmerga Army bounce back from serious injuries. Indian High Commissioner attended the meeting Consul general of India Subhash C. Kain attended a meeting with the commander in chief Houshmmad of Peshmerga & Major Dr. Dana A. Ali

Stem cells therapy can be used for the treatment of injuries where surgery does not heal wounds of skin muscles, tendons, bones, the sensory part, solid organs, nervous system and other skeleton muscle and pulmonary tissues , also it will look into radiation syndromes to treat using stem cells.

Stem cell therapy has been a boon for a large number of patients and is becoming increasingly popular. It is used to treat complex diseases without any complications. Stem cell therapy will not only yield positive results in common people but army men too. The Peshmerga forces have sacrificed a lot during the war against the ISIS terrorist group in the last decade to protect their country and the entire world from terrorist threats. Unfortunately, as a result of the war, besides thousands of Peshmerga have been martyred, more than 10,000 peshmergas have been injured critically. Some of them are fully healed, while others still need to be treated. To promptly tackle the need of the soldiers, Dr Pradeep Mahajan has been invited by the Ministry of Peshmerga, Kurdistan.

Dr Pradeep Mahajan, Regenerative Medicine Researcher, StemRx Bioscience Solutions Pvt. Ltd said, It was an honor to deliver a lecture on stem cell therapy for Peshmerga forces in Kurdistan. If there is war then there are going to be injuries. I briefed them about how revolutionary stem cell therapy can be a game changer for them when it comes to untreatable diseases. I respect the army men for their courage, spirit, and love towards the country. It was a proud moment for me to deliver a lecture for them. I hope to get more such opportunities in the near future and help the army men to overcome injuries and improve their quality of life.

It is a proud moment for the Indian Community to extend the high technology to improve the recovery of a war injury.

See original here:
Stem Cell Therapy Approach On War Injury Patients - NewsPatrolling

New Method Promises to Yield More Therapeutic T Cells – Medscape

Producing the T lymphocytes that are increasingly being used to fight cancer and other diseasesmay soon be faster and more efficient, thanks to research being conducted at the University of British Columbia, in Vancouver, Canada.

Investigators found that adding the human proteins DLL4 and VCAM1 rather than using traditional animal products during a key cellular transition phase enhanced downstream output of progenitor T cells from pluripotent stem cells (PSCs) about 80-fold. The recombinant human proteins targeted the endothelial-to-hematopoietic (EHT) phase of development. If scaled up, the new process could substantially increase the availability and affordability of personalized T-cell immunotherapy.

Dr Yale Michaels

"Our goal is to be able to take cells from human donors, genetically modify and produce them in high numbers, and then store them in the freezer for off-the-shelf medicine," study author Yale S. Michaels, DPhil, postdoctoral fellow in biomedical engineering, told Medscape Medical News. "We think our technique will be ready for trials in humans within a couple of years."

The findings were published online August 24 in Science Advances.

Chimeric antigen receptor and engineered T-cell receptor T cells have demonstrated high clinical efficacy against some cancers. They also show promise for treating infection and immunologic disorders and for preventing transplant rejection, the authors write.

But sourcing these therapeutic cells from individual donors is costly and laborious, they add. Inter-donor variability and intra-donor heterogeneity make the production and quality control of personalized T-cell therapies challenging. The efficacy rate of this type of therapy is close to 50% for some cancers, but a new batch must be created for each treatment, and the cost is about half a million dollars each round, according to the researchers. Using PSCs to create immune cells in the laboratory could facilitate the derivation of hundreds of doses from a single cell.

Differentiating PSCs specifically into hematopoietic progenitors with T-cell potential remains difficult. "How to make the right type of cells from PSCs in the lab has been really challenging," said Michaels. "Previously, shepherd, or guide, cells from mouse cell lines or cow serum were used, but these shepherd cells produce so many different factors and components that it was hard to understand the minimum signals necessary to do the required job."

Michaels and his team believed that a pathway called notch signaling, which DLL4 and VCAM1 help to activate, would be important in the development of differentiated blood cells. As it turns out, VCAM1 cooperates with DLL4 to enhance the magnitude of notch signaling during the EHT culture phase. "We set out to understand the minimal signaling requirements for generating hematopoietic progenitors with T-cell potential from human PSCs," said Michaels.

The investigators coated lab Petri dishes with the DLL4 and VCAM1 proteins and added stem cells and growth media to foster the growth of blood cells with T-cell potential. "Production became faster and more efficient. As an added advantage, without the use of animal products, manufacturing can be done in a quality-controlled way that is easy to replicate and will make it suitable for clinical use," said Michaels.

Unexpectedly, the investigators also found that VCAM1 promoted inflammatory-responsive gene expression in hematopoietic stem cells. Studies in zebrafish and mice have shown that inflammatory signals are important for the emergence of these cells, both upstream and downstream of the notch pathway, they note.

Offering an oncologist's perspective, Cassian Yee, MD, a professor of melanoma medical oncology and immunology at the University of Texas MD Anderson Cancer Center in Houston, agreed that ultimately, the goal is to prescribe off-the-shelf treatment with T cells designed for a given cancer type and stage. "The method described by Michaels et al is a significant step in that direction," he told Medscape. The technique "utilizes well-defined reagents that could likely be rendered clinical-grade compatible for ex vivo manufacturing and is able to produce a diverse T-cell repertoire." Yee was not involved in the current study.

Dr Cassian Yee

But many steps remain before that goal is reached, Yee cautioned. Among them are identifying and engineering T cells with the desired specificity, enriching and expanding them efficiently from a PSC-derived product with the desired intrinsic properties, and achieving scalability. "But I believe that ultimately, these issues are all addressable and this technology opens the door a little wider to that possibility," said Yee.

The research was funded by Notch Therapeutics, the Stem Cell Network Fueling Biotechnology Partnerships, the Canadian Institute for Health Research Foundation, and the Wellcome Leap Human Organs, Physiology, and Engineering program. Michaels is an inventor of patents relating to T-cell differentiation and consults for regenerative medicine companies, including Notch Therapeutics. Yee sits on the advisory boards of several cell therapy companies, but none are engaged in research relevant to his comments.

Sci Adv. Published online August 24. Full text

Diana Swift is a medical journalist based in Toronto. She can be reached at dianaswift@rogers.com.

For more news, follow Medscape on Facebook, Twitter, Instagram, and YouTube.

Visit link:
New Method Promises to Yield More Therapeutic T Cells - Medscape

Cell Therapy And Acellular Therapy Market See Huge Growth for New Normal | Aegle Therapeutics Corp, ArunA Biomedical – Fighting Hawks Magazine -…

California (United States) Cell Therapy And Acellular Therapy Market research is an intelligence report with meticulous efforts to study the right and valuable information. The data that has been looked upon is done considering the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well-explained SWOT analysis, revenue share, and contact information are shared in this report analysis.

Get the PDF Sample Copy (Including FULL TOC, Graphs, and Tables) of this report @:

Some of the Top companies Influencing this Market include:

Aegle Therapeutics Corp, ArunA Biomedical, Capricor Therapeutics, Inc., Codiak BioSciences, Inc., Direct Biologics, LLC, EV Therapeutics, Inc., Evox Therapeutics Ltd, Exogenus Therapeutics, Invitrx Therapeutics, Inc., Organicell Regenerative Medicine, Inc., Rion LLC, Stem Cell Medicine Ltd..

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists the restraints that are posing a threat to the global

Global Cell Therapy And Acellular Therapy Market Segmentation:

Market Segmentation: By Type

Cell Therapy Acellular Therapy

Market Segmentation: By Application

Cardiology Hepatology Neurology Gastroenterology Oncology

The report provides insights on the following pointers:

Market Penetration: Comprehensive data on the product portfolios of the top players in the Cell Therapy And Acellular Therapy market.

Product Development/Innovation: Detailed information about upcoming technologies, R&D activities, and market product debuts.

Competitive Assessment: An in-depth analysis of the markets top companies market strategies, as well as their geographic and business segments.

Market Development: Information on developing markets in their entirety. This study examines the market in several geographies for various segments.

Market Diversification: Extensive data on new goods, untapped geographies, recent advancements, and investment opportunities in the Cell Therapy And Acellular Therapy market.

Get Up to 30% Discount on the first purchase of this report @:

Global Cell Therapy And Acellular Therapy market Report Scope:

The cost analysis of the Global Cell Therapy And Acellular Therapy Market has been performed while considering manufacturing expenses, labor cost, and raw materials and their market concentration rate, suppliers, and price trend. Other factors such as Supply chain, downstream buyers, and sourcing strategy have been assessed to provide a complete and in-depth view of the market. Buyers of the report will also be exposed to a study on market positioning with factors such as target client, brand strategy, and price strategy considered.

Key questions answered in this report:

Table of Contents

Global Cell Therapy And Acellular Therapy Market Research Report 2022 2029

Chapter 1 Cell Therapy And Acellular Therapy Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy, and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Cell Therapy And Acellular Therapy Market Forecast

Buy Exclusive Report:

If you have any special requirements, please let us know, and we will offer you the report as you want.

About A2Z Market Research:

The A2Z Market Research library provides syndication reports from market researchers around the world. Ready-to-buy syndication Market research studies will help you find the most relevant business intelligence.

Our Research Analyst Provides business insights and market research reports for large and small businesses.

The company helps clients build business policies and grow in that market area. A2Z Market Research is not only interested in industry reports dealing with telecommunications, healthcare, pharmaceuticals, financial services, energy, technology, real estate, logistics, F & B, media, etc. but also your company data, country profiles, trends, information and analysis on the sector of your interest.

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

+1 775 237 4157

Cell Therapy And Acellular Therapy, Cell Therapy And Acellular Therapy market, Cell Therapy And Acellular Therapy market research, Cell Therapy And Acellular Therapy market report, Cell Therapy And Acellular Therapy Market comprehensive report, Cell Therapy And Acellular Therapy market forecast, Cell Therapy And Acellular Therapy market growth, Cell Therapy And Acellular Therapy Market in Asia, Cell Therapy And Acellular Therapy Market in Australia, Cell Therapy And Acellular Therapy Market in Europe, Cell Therapy And Acellular Therapy Market in France, Cell Therapy And Acellular Therapy Market in Germany, Cell Therapy And Acellular Therapy Market comprehensive analysis, COVID 19 impact on Cell Therapy And Acellular Therapy market, Aegle Therapeutics Corp, ArunA Biomedical, Capricor Therapeutics, Inc., Codiak BioSciences, Inc., Direct Biologics, LLC, EV Therapeutics, Inc., Evox Therapeutics Ltd, Exogenus Therapeutics, Invitrx Therapeutics, Inc., Organicell Regenerative Medicine, Inc., Rion LLC, Stem Cell Medicine Ltd.

Read more:
Cell Therapy And Acellular Therapy Market See Huge Growth for New Normal | Aegle Therapeutics Corp, ArunA Biomedical - Fighting Hawks Magazine -...

Global Cell Culture Market to Grow by 11.99% Annually Through 2029 – ResearchAndMarkets.com – Business Wire

DUBLIN--(BUSINESS WIRE)--The "Cell Culture Market Analysis by Product, by Application, by End User, and by Region - Global Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.

The global cell culture market size is valued to be USD 19.78 billion in 2021 and is anticipated to witness a CAGR of 11.99% during the forecast period. Growth in awareness regarding the advantages of cell culture-based vaccines is a key driver for the growth of the global cell culture market. Additionally, increase in demand for monoclonal antibodies and subsidy offered to cell-based research in the cell culture market is some of the other drivers propelling the market growth. Nevertheless, high cost of cell culture treatment and shortage of structure for cell-based research in emerging economies are expected to restrain the global market growth.

By Product

Based on product segment, the market is sub-segmented into consumables and equipment. In 2021, the consumables segment accounted for a substantial revenue share and is expected to grow with a lucrative CAGR during the forecast period. This is attributed to the recurrent purchase of consumables along with increasing subsidy for cell-based research. worldwide. Equipment segment is projected to grow at a profitable CAGR during the forecast period. This is attributed to the increasing risk of pandemic and communicable diseases.

By Application

Based on application, the market is segmented into biopharmaceutical production, diagnostics, drug screening and development, stem cell research, tissue engineering & regenerative medicine, and other applications. In 2021, the biopharmaceutical production segment accounted for a substantial revenue share and is expected to grow with a lucrative CAGR during the forecast period. This is attributed to growing governing sanctions for the manufacture of cell culture-based vaccines along with an increasing demand for monoclonal antibodies (mAbs) worldwide. Stem cell research segment is expected to grow at a profitable CAGR during the forecast period. This is attributed to the growth in advancements of proteomic gene expression and consequent growth of new vaccine and biopharmaceuticals globally.

By End User

Based on end user, the market is categorized into cell banks, pharmaceutical & biotechnology companies, academic & research institutes, and hospitals and diagnostic laboratories. In 2021, the pharmaceutical & biotechnology companies segment accounted for a substantial revenue share and is expected to grow with a lucrative CAGR during the forecast period. This is due to the growth in application of single-use technologies along with the increase in number of regulatory sanctions for manufacturing of cell culture-based vaccines worldwide. The cell banks segment is anticipated to grow at a profitable CAGR during the forecast period, due to the rise in incidence of chronic diseases that have resulted in increase in cell biology & cytological studies.

Consumables

Bioreactor Accessories

Equipment

Supporting Equipment

Other Supporting Equipment

Single-Use Bioreactors

Storage Equipment

Cell Culture Market, By Application (Revenue, USD Billion, 2021-2029)

Biopharmaceutical Production

Cell Culture Market, By End User (Revenue, USD Billion, 2021-2029)

Cell Culture Market, By Region (Revenue, USD Billion, 2021-2029)

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Key Topics Covered:

1. Research Methodology

2. Introduction: Cell Culture

3. Executive Summary

4. Market Dynamics

5. Market Environment Analysis

6. COVID-19 Impact Analysis: Cell Culture Market

7. Market Analysis by Product

8. Market Analysis by Application

9. Market Analysis by End User

10. Regional Market Analysis

11. North America Cell Culture Market

12. Europe Cell Culture Market

13. Asia Pacific Cell Culture Market

14. Latin America Cell Culture Market

15. MEA Cell Culture Market

16. Competitor Analysis

17. Company Profiles

18. Conclusion & Recommendations

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/g47hlz

Originally posted here:
Global Cell Culture Market to Grow by 11.99% Annually Through 2029 - ResearchAndMarkets.com - Business Wire

Global Exosome Market Report 2022: Integration into Fields of Liquid Biopsy, Precision Medicine, and Regenerative Medicine Driving Growth – Yahoo…

Company Logo

Dublin, Sept. 06, 2022 (GLOBE NEWSWIRE) -- The "The Global Exosome Market - Market Size, Forecast, Trials, and Trends, 2022" report has been added to ResearchAndMarkets.com's offering.

Exosome technologies have been developing rapidly in recent years and substantial growth is expected for the market as they get integrated into the fields of liquid biopsy, precision medicine, and regenerative medicine. In particular, cancer-derived exosomes influence the invasive potential of cells by regulating angiogenesis, metastasis, and immunity, making them an extremely useful source of biomarkers for use in cancer detection, diagnosis, and therapeutic selection.

The cargo contained within exosomes can offer prognostic information for a range of diseases - including cardiovascular, renal, neurodegenerative, and metabolic diseases - as well as cancer. Researchers investigating exosome biomarkers have discovered, identified, and reported the presence of hundreds of biomolecules within the lumen of exosomes. This discovery has compelled a rapid rise in exosome-related cancer biomarker research, including the use of exosomes for the detection, monitoring, and treatment of a diverse range of oncologic conditions.

Importantly, exosomes are present within a diverse range of biofluids, including serum, plasma, urine, seminal fluid, CSF, saliva, tears, and breast milk. For this reason, exosome-based diagnostics are minimally invasive, offering ease of use and speed of detection. Exosomes can also act as prognostic indicators and predictors of a patient's response to a specific course of treatment.

Exosomes are also being explored for their use as cell-free therapeutics. For example, if a patient has a disease caused by a missing or defective protein or microRNA, the patient's exosomes can be isolated, modified with the appropriate siRNA or protein, and injected back into the patient for treatment. Numerous approaches are being researched for creating drug-loaded exosomes and exosomes themselves can exert powerful effects. For example, mesenchymal stem cell (MSC) derived exosomes have the capacity to suppress inflammation, prevent scar tissue formation, and mediate a healthy immune response.

Story continues

The Era of Exosomes

For these reasons, exosomes have gone from being overlooked to rapidly gaining momentum as a novel strategy for accessing the therapeutic effects of cells without the risks and difficulties of administering cells to patients. Although exosomes were discovered more than 30 years ago, it was not until recently that the scientific community began to credit exosomes for a range of promising traits.

To date, three pharma companies (Takeda, Jazz Pharmaceuticals, and Roche Pharmaceutical Company) have signed partnership deals with exosome companies offering payment terms structured to deliver at or around $1 billion dollars. Within the past 5 years, there have been at least 7 partnership deals within the exosome industry, 8 large venture capital events, and 2 landmark acquisitions.

Today the exosome industry is witnessing:

A surging number of scientific papers investigating exosomes and their applications

Rising numbers of clinicals trials investigating exosome therapeutics and diagnostics

Swelling appetite among investors for exosome technology

An increasingly competitive IP environment

A diverse range of co-development partnerships

Proliferating numbers of exosome competitors in all major life science markets worldwide

This global strategic report about the exosome industry reveals:

The clinical pipeline for exosome therapeutics

Clinical trial activity by type, region, phase, and sponsor

Exosome industry events, including M&A activity, financing events, and IPOs

Strategic partnerships and co-development agreements

Competitors composing the global marketplace, including core technologies and products under development

Market size determinations by market segment, with forecasts through 2030

Exosome industry trends, competitive opportunities, and future directions.

Key Topics Covered:

1. REPORT OVERVIEW

2. EXOSOMES: AN OVERVIEW

3. EXOSOME ENGINEERING: THE NEW PLATFORM

4. MSC-DERIVED EXOSOMES IN REGENERATIVE MEDICINE

5. EXOSOME RESEARCH

6. COMMERCIALLY AVAILABLE EXOSOME RESEARCH TOOLS

7. SCIENTIFIC PUBLICATIONS IN EXOSOMES

8. EXOSOME PATENT LANDSCAPE

9. EXOSOMES: CLINICAL TRIAL LANDSCAPE

10. CURRENT STATUS OF EXOSOME MANUFACTURING

11. EXOSOME ISOLATION APPROACHES

12. DIAGNOSTIC APPLICATIONS OF EXOSOMES

13. THERAPEUTC APPLICATIONS OF EXOSOMES

14. APPLICATION OF EXOSOMES IN VACCINE DEVELOPMENT

15. CURRENT STATUS OF EXOSOME INDUSTRY

16. EXOSOME MARKET ANALYSIS

17. PROFILES OF EXOSOME MARKET COMPETITORS Companies Mentioned

101 Bio

AB

Abbexa, Ltd.

Abnova

Acquisition by Therillia

Adipomics, Inc.

Aegle Therapeutics

Aethlon Medical, Inc.

AgeX Therapeutics

Ambiotech

AmnioStem Stroke Therapy

AmniWrap

AMS Biotechnology, Ltd. (AMSBIO)

Anjarium Biosciences

Anjarium's Hybridosome Platform

Antibodies-Online GmbH

Aposcience AG

Aruna Bio

Avalon GloboCare Corp.

Avalon's Core Platforms

Aviva Systems Biology

AZ Platform

Azymus Therapeutics

Beckman Coulter Life Sciences

Bio-Techne

BioCat GmbH

BioDrone Technology

BioFluidica

Biological Dynamics, Inc.

Biorbyt, Ltd.

BioRegenerative Sciences, Inc.

BioVision, Inc.

BrainStorm Cell Therapeutics

BreStem Therapeutics, Inc.

Capricor Therapeutics

Carmine Therapeutics

CBD-Loaded Exosomes

CCT-

CD Bioparticles

Cell Care Therapeutics

Cell Factory BVBA/Esperite NV

Cell Guidance Systems, Ltd.

Cellarcus Biosciences, Inc.

Cevaris Plexaris

Ciola

CK-Exogene

Clara Biotech

Codiak Biosciences

Coya Therapeutics, Inc.

Craif, Inc.

Creative Bioarray

Creative Biolabs

Creative Medical Technology Holdings

Creative Proteomics

CreativeBiostructure

Curexsys GmbH

CUSABIO TECHNOLOGY LLC

Original post:
Global Exosome Market Report 2022: Integration into Fields of Liquid Biopsy, Precision Medicine, and Regenerative Medicine Driving Growth - Yahoo...

Regenerative Medicine: An alternative to surgery and pills | Loop Cayman Islands – Loop News Cayman

Surgical methods of repair have long since been touted as the best approach to treatment and healing for patients with long-term, degenerative conditions.

While effective, factors such as high costs, long downtime, surgical complications and more can be a deterrent for patients who are considering surgery for non-life-threatening conditions.

Regenerative Medicine is an approach available for some patients who are seeking pain relief and long-term healing and would like to reduce the need for surgery.

Regenerative medicine can be defined as the process of replacing or regenerating human cells or tissues to facilitate healing and repair. The ability to encourage this repair in the human body reduces the time most patients will remain ill and offers many possibilities in the field of medicine.

In understanding the regenerative process, it is important to note that the potential for repair and the ability to repair are two separate things. We all have the potential to repair but we dont all have the ability. Increasing the ability to repair is considered one of the main benefits of regenerative medicine. This is derived from the ability of cells, particularly stem cells, to promote cell repair by reducing inflammation which promotes faster healing, better circulation and less pain in an injured area.

Stem cells can be taken from a variety of tissues in the body, and they tend to be harvested from areas that are easily accessible. With stem cell therapy, you are able to use your bodys own repair team (cells) to heal an injured area.

In fact, stem cell therapy has been proven to regenerate tissue in the human body without the need for surgery or additional medication in certain conditions. It is useful for patients who are suffering from degenerative and chronic diseases, such as chronic pain, who are in search of medical treatments without surgical interference.

Image via iStock

Regenerative Medicine and Stem Cell Therapy are useful treatment options for:

The typical patient is over 40 years perhaps starting to experience some joint pains, sexual dysfunction or lack of energy aging with an inability to keep up with their demanding lifestyles.

One patient, DG, came in for a list of concerns that are typical in a 60-year-old including knee pain, mild erectile dysfunction and high blood pressure.

One patient reported improved eyesight among other benefits after his treatment. Image via iStock

DG underwent stem cell therapy and reports to us on his experience. He reported an overwhelming relief from pain and the anxiety associated with expecting this pain. His knee, which was injured during an uphill walk, has had improvement and he is able to enjoy his daily walks without expectation of pain. He also marveled at the maintenance of life and health aspect of Stem Cell Therapy which enabled him to bank his extracted Stem Cells for future usage.

Lastly, DG mentioned the unexpected benefits that have come from the treatment such as improved eyesight without glasses, a reduction of graying hairs, a reduction in bags under the eye, a younger appearance and a reduction of Erectile Dysfunction!

BioRegeneration Integrated Medical Centre in Jamaica specialises in stem cell therapy using your own stem cells. This treatment is done locally by Dr Janice Simmonds-Fisher who has pioneered Regenerative Medicine in Jamaica for over a decade providing a life-improving treatment that enjoys over 90 per centsuccess rate in our population.

BioRegeneration is located at 15 Haining Road, Kingston. They can be contacted at 876-552-6484. For any questions, email questions@drjanicefisher.com or visit http://www.stemcelljamaica.com.

For our regional patients, Dr. Fisher offers phone or virtual consultations. To make a virtual consultation appointment, please email questions@drjanicefisher.com or whatsapp 876-565-1168.

The rest is here:
Regenerative Medicine: An alternative to surgery and pills | Loop Cayman Islands - Loop News Cayman

Global Stem Cell Banking Market To Be Driven At A CAGR Of 13.5% In The Forecast Period Of 2021-2026 This Is Ardee – This Is Ardee

The new report by Expert Market Research titled, Global Stem Cell Banking Market Report and Forecast 2021-2026, gives an in-depth analysis of the globalstem cell banking market, assessing the market based on its segments like Service type, product type, utilisation, bank type, application, and major regions like Asia Pacific, Europe, North America, Middle East and Africa and Latin America. The report tracks the latest trends in the industry and studies their impact on the overall market. It also assesses the market dynamics, covering the key demand and price indicators, along with analysing the market based on the SWOT and Porters Five Forces models.

Request a free sample copy in PDF or view the report summary@https://bityl.co/CPix

The key highlights of the report include:

Market Overview (2021-2026)

The global stem cell bank market is primarily driven by the advancements in the field of medicine and the rising prevalence of genetic and degenerativediseases. Further, the increasing research and development of more effective technologies for better preservation, processing, and storage of stem cells are aiding the growth. Additionally, rising prevalence of chronic diseases globally is increasing the for advances inmedicaltechnologies, thus pushing the growth further. Moreover, factors such as rising health awareness, developinghealthcare infrastructure, growing geriatric population, and the inflatingdisposableincomes are expected to propel the market in the forecast period.

Industry Definition and Major Segments

Stem cells are undifferentiated cells present in bone marrow,umbilical cordadipose tissue and blood. They have the ability to of differentiate and regenerate. The process of storing and preserving these cells for various application such as gene therapy, regenerative medicine and tissue engineering is known as stem cell banking.

Explore the full report with the table of contents@https://bityl.co/CPiy

By service type, the market is divided into:

Based on product type, the industry can be segmented into:

The market is bifurcated based on utilization into:

By bank type, the industry can be broadly categorized into:

Based on application, the industry can be segmented into:

On the basis of regional markets, the industry is divided into:

1 North America 1.1 United States of America 1.2 Canada 2 Europe 2.1 Germany 2.2 United Kingdom 2.3 France 2.4 Italy 2.5 Others 3 Asia Pacific 3.1 China 3.2 Japan 3.3 India 3.4 ASEAN 3.5 Others 4 Latin America 4.1 Brazil 4.2 Argentina 4.3 Mexico 4.4 Others 5 Middle East & Africa 5.1 Saudi Arabia 5.2 United Arab Emirates 5.3 Nigeria 5.4 South Africa 5.5 Others

Market Trends

Regionally, North America is projected to dominate the global stem cell bank market and expand at a significant rate. This can be attributed to increasing research and development for stem cell application in various medical fields. Further, growing investments of pharmaceutical players and development infrastructure are other factors that are expected to stem cell bank market in the region. Meanwhile, Asia Pacific market is also expected to witness fast growth owing to the rapid development in healthcare facilities and increasing awareness of stem cell banking in countries such as China, India, and Indonesia.

Key Market Players

The major players in the market are Cryo-Cell International, Inc., Smart Cells International Ltd., CSG-BIO Company, Inc., CBR Systems Inc., ViaCord, LLC, LifeCell International Pvt. Ltd., and a few others. The report covers the market shares, capacities, plant turnarounds, expansions, investments and mergers and acquisitions, among other latest developments of these market players.

About Us:

Expert Market Research (EMR) is leading market research company with clients across the globe. Through comprehensive data collection and skilful analysis and interpretation of data, the company offers its clients extensive, latest and actionable market intelligence which enables them to make informed and intelligent decisions and strengthen their position in the market. The clientele ranges from Fortune 1000 companies to small and medium scale enterprises.

EMR customises syndicated reports according to clients requirements and expectations. The company is active across over 15 prominent industry domains, including food and beverages, chemicals and materials, technology and media, consumer goods, packaging, agriculture, and pharmaceuticals, among others.

Over 3000 EMR consultants and more than 100 analysts work very hard to ensure that clients get only the most updated, relevant, accurate and actionable industry intelligence so that they may formulate informed, effective and intelligent business strategies and ensure their leadership in the market.

Media Contact

Company Name: Claight Corporation Contact Person: Steven Luke, Corporate Sales Specialist U.S.A. Email:sales@expertmarketresearch.com Toll Free Number: +1-415-325-5166 | +44-702-402-5790 Address: 30 North Gould Street, Sheridan, WY 82801, USA Website:https://www.expertmarketresearch.com

Read More Reports:

Cold Pressed Sesame Oil Market: https://freighteurasia.com/global-cold-pressed-sesame-oil-market-to-be-driven-by-the-rising-uses-of-the-oil-in-alternative-medicine-cooking-and-body-massage-in-the-forecast-period-of-2022-2027/

Malaysia Cordial Drink Market: https://freighteurasia.com/malaysia-cordial-drink-market-to-be-driven-by-rising-demand-for-non-alcoholic-and-non-carbonated-beverages-to-aid-the-growth-of-the-cordial-drink-industry-in-malaysia-in-the-forecast-period-of-2021-20/

Sodium Diacetate Market: https://freighteurasia.com/global-sodium-diacetate-market-to-be-driven-by-the-increase-in-the-consumption-of-processed-foods-in-the-forecast-period-of-2021-2026/

Volute Pumps Market: https://freighteurasia.com/global-volute-pumps-market-to-be-driven-by-the-increasing-expenditure-on-infrastructure-development-in-the-forecast-period-of-2021-2026/

Myristic Acid Market: https://freighteurasia.com/global-myristic-acid-market-to-be-driven-by-the-increase-in-the-demand-for-flavoured-foods-and-drinks-in-the-forecast-period-of-2021-2026/

*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.

Read this article:
Global Stem Cell Banking Market To Be Driven At A CAGR Of 13.5% In The Forecast Period Of 2021-2026 This Is Ardee - This Is Ardee

Diabetic foot treatment: Here’s all you need to know about stem cell therapy – Hindustan Times

Diabetes is nothing less than a pandemic as according to the World Health Organization, about 422 million people have diabetes worldwide. High blood sugar levels affect different organs and tissues of the body leading to a compromised quality of life for example, you might have experienced or heard of tingling sensation, numbness, or pain in the legs/feet of patients with diabetes which as per the health experts, occur due to nerve and blood circulation-related problems caused by the negative effects of high glucose levels on cells and tissues.

Foot-related problems occur commonly in patients with diabetes like if we hurt our toe/foot and have an open wound or cut, the nerve endings from the affected part send signals to the brain and cause pain. In case a person with uncontrolled and long-standing diabetes, the sensation of pain may not be transmitted properly due to nerve issues, leading to the patient ignoring the problem and in such cases, even a small cut can progress to a large size wound (as we know wound healing is affected in diabetic patients).

Infection can spread from the feet through the blood to other parts of the body as well and in the feet specifically, increased severity of the issue can lead to gangrene, ultimately necessitating amputation of the toes/foot. It is therefore important to look out for issues such as cuts, bruises, red spots, warm areas, swelling, blisters, corn, etc. in the feet to identify any issue at the earliest and initiate treatment.

From an advanced treatment perspective, Dr Pradeep Mahajan, Regenerative Medicine Researcher at Navi Mumbai's StemRx Bioscience Solutions Pvt Ltd, talked about regenerative medicine for diabetic foot in an interview with HT Lifestyle. He explained, Regenerative medicine is about using biological molecules to enhance the healing potential of the body. These molecules are cells, growth factors, exosomes, peptides, all of which function to enhance the function of other cells in the body, reduce inflammation, regulate the immune system, provide a constant pool of healthy cells, and clear tissue damage, among other functions.

He highlighted that the treatment for diabetic foot includes a combination of mesenchymal stem cells, growth factors that improve nerve health and blood vessel formation, oxygen therapy, as well as allied stimulation-based treatments. He said, We have seen successful outcomes in diabetic foot conditions following cell-based therapy. Patients experience relief from abnormal sensations in the feet, better wound healing and pain along with better control of diabetes.

Dr Mahajan added, When we target the pathology, we get more definitive treatment outcomes. Our patients with diabetic foot do not progress to develop gangrene. In fact, they even achieve better control of blood glucose levels, which prevents further complication and improves their quality of life. The key is a regenerative (not symptomatic) treatment along with lifestyle modifications.

Here is the original post:
Diabetic foot treatment: Here's all you need to know about stem cell therapy - Hindustan Times